Efficacy and Safety of Once- Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial

Andrew J. Ahmann,1 Matthew Capehorn,2 Guillaume Charpentier,3 Francesco Dotta,4 Elena Henkel,5 Ildiko Lingvay,6 Anders G. Holst,7 Miriam P. Annett,8 and Vanita R. Aroda9 *** Diabetes Care 2018;41:258–266 | https://doi.org/10.2337/dc17-0417